Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol intrapulmonary concentrations in bacterial pneumonia
NCT03862040Phase 1Terminated
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cefiderocol in bacterial pneumonia, sponsored by Shionogi & Co., Ltd. Primary endpoints: Concentration of Cefiderocol in Epithelial Lining Fluid at 40 hours and Ratio of the Concentration of Cefiderocol in Epithelial Lining Fluid Relative to Plasma at 40 hours. Started Feb 2019; status: terminated.
02
Drugs
cefiderocol
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT03862040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862040.